The effect of sleep disorders on health and the possibility of correction of sleep disorders
https://doi.org/10.21518/2079-701X-2018-18-30-33
Abstract
Treatment of insomnia is an important medical and social problem due to its widespread prevalence and significant negative impact on human health. The state of chronic cerebral hyper-activation, which has cognitive, electrophysiological and metabolic manifestations, plays an important role in the development of insomnia. The sleep disorder has been proven to be a risk factor for the development of arterial hypertension, metabolic syndrome, immunodeficiency disorder and cognitive impairment. Nonmedicinal and medicinal products are used to treat insomnia. Cognitive-behavioural therapy may be effective as a psychotherapy. Non-benzodiazepine GABA-receptors agonists are most often used to treat chronic insomnia and histamine receptor blockers to treat acute insomnia among the other drugs of this group.
About the Authors
S. L. Tsenteradze
Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
M. G. Poluektov
Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
References
1. Fitzgerald I, Donlea J, Shaw P. Waking Experience Affects Sleep Need in Drosophila. Science, 2006, 313: 1775– 1781.
2. Vivo L, Bellesi M, Marshall W, Bushong EA, Ellisman MH, Tononi G, Cirelli C. Ultrastructural evidence for synaptic scaling across the wake/sleep cycle. Science, 2017, 355: 507–510.
3. Diering G, Nirujogi R, Roth R, Worley P, Pandey A, Huganir R. Homer1a drives homeostatic scaling-down of excitatory synapses during sleep. Science, 2017, 355: 511–515.
4. Patrick Y, Lee A, Raha O et al. Effects of sleep deprivation on cognitive and physical performance in university students. Sleep Biol Rhythms, 2017, 15(3): 217–225.
5. Центерадзе С.Л., Полуэктов М.Г. Влияние нарушений сна на равновесие в пожилом и старческом возрасте. Эффективная фармакотерапия. Спецвыпуск «Сон и его расстройства-3», 2015, 53: 50-54.
6. Gottlieb DJ, Redline S, Nieto FJ et al. Association of usual sleep duration with hypertension: the Sleep Heart Health Study. Sleep, 2006, 29: 1009-1014.
7. Gangwisch JE, Heymsfi eld SB, Boden-Albala B et al. Short sleep duration as a risk factor for hypertension: analyses of the first National Health and Nutrition Examination Survey. Hypertension, 2006, 47: 833-839.
8. Phillips B, Mannino DM. Do insomnia complaints cause hypertension or cardiovascular disease? J. Clin. Sleep Med, 2007, 3: 489-494.
9. Yanping L et al. Association between sleeping difficulty and type 2 diabetes in women. Diabetologia, 2016, 59(4): 719–727.
10. Yamada T, Shojima N, Yamauchi T, Kadowaki T. J-curve relation between daytime nap duration and type 2 diabetes or metabolic syndrome: A dose-response metaanalysis. Published online 2016. doi: 10.1038/srep38075.
11. Cohen S, Doyle WJ, Alper CM, Janicki-Deverts D, Turner RB. Sleep habits and susceptibility to the common cold. Arch Intern Med, 2009, 169(1): 62-7.
12. Horvath TL, Gao XB. Input organization and plasticity of hypocretin neurons: possible clues to obesity’s association with insomnia. Cell Metab, 2005, 1(4): 279-86.
13. Cai GH, Theorell-Haglöw J, Janson C, Svartengren M, Elmstahl S, Lind L, Lindberg E. Insomnia symptoms and sleep duration and their combined effects in relation to associations with obesity and central obesity. Sleep Med, 2018, 46: 81-87.
14. Foley D, Ancoli-Israel S, Britz P, et al. Sleep disturbances and chronic disease in older adults: results of the 2003 National Sleep Foundation Sleep in America Survey. J Psychosom Res, 2004, 56(5): 497–502.
15. Foley DJ, Monjan AA, Brown SL, et al. Sleep complaints among elderly persons: an epidemiologic study of three communities. Sleep, 1995, 18(6): 425– 432.
16. Ohayon MM, Carskadon MA, Guilleminault C, et al. Metaanalysis of quantitative sleep parameters from childhood to old age in healthy individuals: developing normative sleep values across the human lifespan. Sleep, 2004, 27(7): 1255–1273.
17. Gehrman PR, Martin JL, Shochat T, et al. Sleepdisordered breathing and agitation in institutionalized adults with Alzheimer disease. Am J Geriatr Psychiatry, 2003, 11(4): 426–433.
18. The International classification of sleep disorders [Diagnostic and coding manual]. American Academy of Sleep Medicine. U.S.A.: Darien. 2014.
19. Carson S, McDonagh MS, Thakurta S, Yen PY. Drug Class Review: Newer Drugs for Insomnia: Final Report Update 2 [Internet]. Portland (OR): Oregon Health & Science University. 2008.
20. Wyatt JK, Dijk DJ, De Cecco AR, et al. Sleep-facilitating effect of exogenous melatonin in healthy young men and women is circadian-phase dependent. Sleep, 2006, 29: 609-18.
21. Haas HL, Sergeeva OA, Selbach O. Histamine in the nervous system. Physiol Rev, 2008, 88: 1183-1241.
Review
For citations:
Tsenteradze SL, Poluektov MG. The effect of sleep disorders on health and the possibility of correction of sleep disorders. Meditsinskiy sovet = Medical Council. 2018;(18):30-33. (In Russ.) https://doi.org/10.21518/2079-701X-2018-18-30-33
Views:
1264
Email this article 